Mar 30, 2021 4:02pm EDT CohBar Reports Fourth Quarter 2020 Financial Results and Provides Business Update
Mar 29, 2021 9:00am EDT CohBar Completes Enrollment in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity
Mar 16, 2021 4:05pm EDT CohBar to Announce 2020 Fourth Quarter Financial Results and Provide Business Update on March 30, 2021
Mar 16, 2021 9:00am EDT CohBar Nominates CB5138 Analog as Lead Clinical Candidate for Idiopathic Pulmonary Fibrosis and other Fibrotic Diseases
Mar 12, 2021 9:00am EST CohBar to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
Jan 11, 2021 9:00am EST CohBar Announces Preclinical Collaboration with NIAID to Evaluate Potential of CB5064 Analogs for Treatment of COVID-19 ARDS